Tandem Diabetes Care
TNDM | NASDAQ
$18.48
-$1.59 (-7.92%)
At close: Nov 16, 2026, 4:00 PM ET
$18.80
+$0.32 (+1.73%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Tandem Diabetes Care Company Profile
Company profile explainedCompany Profile
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Key Executives
| Name | Position |
|---|---|
| John F. Sheridan | President, Chief Executive Officer & Director |
| Jean-Claude E. Kyrillos | Executive Vice President & Chief Operating Officer |
| Leigh A. Vosseller | Executive Vice President, Chief Financial Officer & Treasurer |
| Elizabeth Anne Gasser | Executive Vice President and Chief Strategy & Product Officer |
| Jordan Pinsker | Chief Medical Officer |
| Rick A. Carpenter | Executive VP & CTO |
| Shannon Hansen | Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary |
| Susan Morrison | Executive Vice President & Chief Administrative Officer |
| Tom Fox | Executive VP & Chief Human Resources Officer |
Tandem Diabetes Care
| Country | United States |
| IPO Date | Nov 14, 2013 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 2,500 |
| CEO | John F. Sheridan |
Contact Details
12400 High Bluff Drive San Diego,
California 92130 United States
Stock Details
| Ticker Symbol | TNDM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001438133 |
| CUSIP Number | 875372203 |
| ISIN Number | US8753722037 |
| SIC Code | 3841 |
Recent News
- 18 hours ago / seekingalpha.comTandem: Wait Out The 2027 Transition Before Chasing The Turnaround
- 3 days ago / benzinga.comTandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
- 3 days ago / businesswire.comTandem Mobi Now FDA Cleared as World's First and Only Tubeless AID System with up to Seven Days of Wear
- 4 days ago / businesswire.comTandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
- 10 days ago / marketbeat.comWhat Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
- 11 days ago / seekingalpha.comTandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript
- 11 days ago / zacks.comTandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
- 11 days ago / zacks.comTandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates
- 17 days ago / businesswire.comTandem Diabetes Care Announces Upcoming Conference Presentations
- 19 days ago / zacks.comTandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Add to Watchlist
Select watchlists to add or remove TNDM